Invest Pasadena Study Technology 
socalTECH
JULY 15, 2013
A new study released earlier this month has ranked the Santa Barbara-Santa Maria-Goleta metropolitan area, as well as the San Diego-Carlsbad-San Marcos metropolitan area among the top ten markets for venture capital activity. investment capital venture capita diego barbara santa' in deals in 2012 and 3.3 Provo-Orem, UT; and 10.
socalTECH
FEBRUARY 9, 2011
The number of Southern California related initial public offerings is growing steadily upwards, as Gevo --originally started in Pasadena, and based on technology out of Caltech and UCLA--hit the market this morning. Gevo is just the latest in a surge of companies hitting the public markets which have Southern California links.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
MAY 10, 2018
Behzad Kianmahd: Cross Campus is one of the companies I invested in, as the first, lead investor, about seven years ago. We have a number of locations, including one in Santa Monica, one in Pasadena, one in Downtown, and one in El Segundo and the South Bay Area. Finally, when are you going to start making investments from the fund?
socalTECH
OCTOBER 1, 2008
A study of the venture capital deal flow in Southern California conducted by socalTECH shows that venture capital deals dropped for Q3, to around $720M in deals, in a market dominated by clean technology firms. invested in Q3 of 2007, and down slightly from venture numbers in Q2, when there was approximately $966M in venture deals.
socalTECH
JANUARY 20, 2011
Freebinar is backed by the Pasadena Angels and the Tech Coast Angels. We are targeting small businesses, startups, or anyone who doesn't want to pay the $50 to $100 a month for web conferencing technology. Costin Tuculescu: I cam out of UC Irvine as a software engineer, studying computer science.
socalTECH
AUGUST 2, 2013
Yapert raised a funding round a few weeks ago from the Tech Coast Angels, Desert Angeles, and Pasadena Angels for its mobile apps, which consolidates news and information about your favorite interests. We really started to study the current generation of smartphones and what people do with them. Phil Kelly: It''s kind of interesting.
Xconomy
NOVEMBER 11, 2016
—Oral arguments in the landmark patent fight over ownership of the gene editing technology CRISPR-Cas9 were set for Dec. The Nitto drug is in a Phase 1b study. —The FDA lifted a partial clinical hold , meanwhile, on a planned cell therapy study from Philadelphia and U.K.-based CRISPR DEVELOPMENTS. 6 at the U.S.
Expert insights. Personalized for you.
263 
Let's personalize your content